166 related articles for article (PubMed ID: 29663289)
1. Chitosan Nanoparticles of Gamma-Oryzanol: Formulation, Optimization, and In vivo Evaluation of Anti-hyperlipidemic Activity.
Rawal T; Mishra N; Jha A; Bhatt A; Tyagi RK; Panchal S; Butani S
AAPS PharmSciTech; 2018 May; 19(4):1894-1907. PubMed ID: 29663289
[TBL] [Abstract][Full Text] [Related]
2. Preparation of Chitosan Okra Nanoparticles: Optimization and Evaluation as Mucoadhesive Drug Delivery System.
Brar V; Kaur G
Pharm Nanotechnol; 2018; 6(3):180-191. PubMed ID: 30101724
[TBL] [Abstract][Full Text] [Related]
3. Gamma-oryzanol-loaded calcium pectinate microparticles reinforced with chitosan: optimization and release characteristics.
Lee JS; Kim JS; Lee HG
Colloids Surf B Biointerfaces; 2009 May; 70(2):213-7. PubMed ID: 19171467
[TBL] [Abstract][Full Text] [Related]
4. Bio-fabrication and statistical optimization of polysorbate 80 coated chitosan nanoparticles of tapentadol hydrochloride for central antinociceptive effect: in vitro-in vivo studies.
Patil GB; Surana SJ
Artif Cells Nanomed Biotechnol; 2017 May; 45(3):505-514. PubMed ID: 27017892
[TBL] [Abstract][Full Text] [Related]
5. Chitosan-TPP nanoparticles stabilized by poloxamer for controlling the release and enhancing the bioavailability of doxazosin mesylate:
Aljaeid BM; El-Say KM; Hosny KM
Drug Dev Ind Pharm; 2019 Jul; 45(7):1130-1139. PubMed ID: 30884977
[No Abstract] [Full Text] [Related]
6. Chitosan nanoparticles as a promising approach for pulmonary delivery of bedaquiline.
Rawal T; Patel S; Butani S
Eur J Pharm Sci; 2018 Nov; 124():273-287. PubMed ID: 30176365
[TBL] [Abstract][Full Text] [Related]
7. Preparation, optimization, and in-vitro/in-vivo/ex-vivo characterization of chitosan-heparin nanoparticles: drug-induced gelation.
Shahbazi MA; Hamidi M; Mohammadi-Samani S
J Pharm Pharmacol; 2013 Aug; 65(8):1118-33. PubMed ID: 23837580
[TBL] [Abstract][Full Text] [Related]
8. Marked augmentation of PLGA nanoparticle-induced metabolically beneficial impact of γ-oryzanol on fuel dyshomeostasis in genetically obese-diabetic ob/ob mice.
Kozuka C; Shimizu-Okabe C; Takayama C; Nakano K; Morinaga H; Kinjo A; Fukuda K; Kamei A; Yasuoka A; Kondo T; Abe K; Egashira K; Masuzaki H
Drug Deliv; 2017 Nov; 24(1):558-568. PubMed ID: 28181829
[TBL] [Abstract][Full Text] [Related]
9. Complexation as an approach to entrap cationic drugs into cationic nanoparticles administered intranasally for Alzheimer's disease management: preparation and detection in rat brain.
Hanafy AS; Farid RM; ElGamal SS
Drug Dev Ind Pharm; 2015; 41(12):2055-68. PubMed ID: 26133084
[TBL] [Abstract][Full Text] [Related]
10. Development of Novel Octanoyl Chitosan Nanoparticles for Improved Rifampicin Pulmonary Delivery: Optimization by Factorial Design.
Petkar KC; Chavhan S; Kunda N; Saleem I; Somavarapu S; Taylor KMG; Sawant KK
AAPS PharmSciTech; 2018 May; 19(4):1758-1772. PubMed ID: 29589222
[TBL] [Abstract][Full Text] [Related]
11. Hypolipidemic potential of perillaldehyde-loaded self-nanoemulsifying delivery system in high-fat diet induced hyperlipidemic mice: Formulation, in vitro and in vivo evaluation.
Omari-Siaw E; Zhu Y; Wang H; Peng W; Firempong CK; Wang YW; Cao X; Deng W; Yu J; Xu X
Eur J Pharm Sci; 2016 Mar; 85():112-22. PubMed ID: 26851382
[TBL] [Abstract][Full Text] [Related]
12. Chitosan/sulfobutylether-β-cyclodextrin nanoparticles as a potential approach for ocular drug delivery.
Mahmoud AA; El-Feky GS; Kamel R; Awad GE
Int J Pharm; 2011 Jul; 413(1-2):229-36. PubMed ID: 21540097
[TBL] [Abstract][Full Text] [Related]
13. Development and evaluation of chitosan and chitosan derivative nanoparticles containing insulin for oral administration.
Hecq J; Siepmann F; Siepmann J; Amighi K; Goole J
Drug Dev Ind Pharm; 2015; 41(12):2037-44. PubMed ID: 26006329
[TBL] [Abstract][Full Text] [Related]
14. Development of Timolol Maleate Loaded Chitosan Nanoparticles For Improved Ocular Delivery.
Saroha A; Pandey P; Kaushik D
Pharm Nanotechnol; 2017; 5(4):310-316. PubMed ID: 28847270
[TBL] [Abstract][Full Text] [Related]
15. Chitosan nanoparticles for the oral delivery of tenofovir disoproxil fumarate: formulation optimization, characterization and ex vivo and in vivo evaluation for uptake mechanism in rats.
Shailender J; Ravi PR; Reddy Sirukuri M; Dalvi A; Keerthi Priya O
Drug Dev Ind Pharm; 2018 Jul; 44(7):1109-1119. PubMed ID: 29409342
[TBL] [Abstract][Full Text] [Related]
16. Improved pharmacokinetics and antihyperlipidemic efficacy of rosuvastatin-loaded nanostructured lipid carriers.
Rizwanullah M; Amin S; Ahmad J
J Drug Target; 2017 Jan; 25(1):58-74. PubMed ID: 27186665
[TBL] [Abstract][Full Text] [Related]
17. Formulation, optimization, in vivo pharmacokinetic, behavioral and biochemical estimations of minocycline loaded chitosan nanoparticles for enhanced brain uptake.
Nagpal K; Singh SK; Mishra DN
Chem Pharm Bull (Tokyo); 2013; 61(3):258-72. PubMed ID: 23449195
[TBL] [Abstract][Full Text] [Related]
18. A potential antibacterial wound dressing of cefadroxil chitosan nanoparticles in situ gel: Fabrication, in vitro optimization and in vivo evaluation.
Basha M; AbouSamra MM; Awad GA; Mansy SS
Int J Pharm; 2018 Jun; 544(1):129-140. PubMed ID: 29655798
[TBL] [Abstract][Full Text] [Related]
19. In-situ forming chitosan implant-loaded with raloxifene hydrochloride and bioactive glass nanoparticles for treatment of bone injuries: Formulation and biological evaluation in animal model.
Abdel-Salam FS; Elkheshen SA; Mahmoud AA; Basalious EB; Amer MS; Mostafa AA; Elkasabgy NA
Int J Pharm; 2020 Apr; 580():119213. PubMed ID: 32165229
[TBL] [Abstract][Full Text] [Related]
20. Formulation and corneal permeation of ketorolac tromethamine-loaded chitosan nanoparticles.
Fathalla ZM; Khaled KA; Hussein AK; Alany RG; Vangala A
Drug Dev Ind Pharm; 2016; 42(4):514-24. PubMed ID: 26407208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
